MELD and MELD-Na score (also searched with possessive/alternate eponym spelling where applicable, ICD-10: K72.90) is a rigorously validated, objective mathematical model utilized worldwide to assess the severity of chronic liver disease and predict short-term mortality in waitlisted candidates for liver transplantation 2,5. Originally developed to predict survival following the placement of a transjugular intrahepatic portosystemic shunt (TIPS), the Model for End-Stage Liver Disease (MELD) was subsequently adopted to prioritize donor liver allocation by estimating native 90-day mortality without the need for subjective clinical criteria such as the Child-Pugh classification 5,6. Because hyponatremia is an independent and powerful predictor of mortality in decompensated cirrhosis, the incorporation of serum sodium yielded the MELD-Na score, refining prognostic accuracy and reducing waitlist mortality for patients with severe ascites and circulatory dysfunction 1,2.

Etiology & Risk Factors

  • Advanced Chronic Liver Disease: End-stage fibrosis and cirrhosis arising from diverse etiologies, including alcohol-associated liver disease, hepatitis C and B virus infections, non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, and primary sclerosing cholangitis2,4.
  • Acute-on-Chronic Liver Failure (ACLF): Sudden deterioration of pre-existing chronic liver disease triggered by precipitants such as bacterial infections, acute alcohol intake, or gastrointestinal hemorrhage, resulting in multi-organ failure and surging MELD scores1,7.
  • Renal Comorbidities: Functional renal impairment, hepatorenal syndrome, or intrinsic glomerulonephritis that elevate serum creatinine and significantly amplify the calculated MELD score2,5.
  • Coagulopathic States: Deficient hepatic synthesis of vitamin K-dependent clotting factors driven by severe hepatocellular parenchymal loss, manifesting as an elevated international normalized ratio (INR)2,5.
  • Cholestatic Insults: Severe biliary stasis, ductopenia, or decompensated biliary obstruction leading to marked hyperbilirubinemia, a core variable within the predictive equations5,6.

Pathophysiology

The pathophysiological foundation of the MELD score rests on the multi-systemic consequences of progressive hepatic parenchymal destruction and portal hypertension 2,3. As functional hepatocyte mass diminishes, the liver fails to conjugate and excrete bilirubin, leading to clinical jaundice and elevated serum levels 5,6. Simultaneously, impaired hepatic synthetic capacity halts the production of coagulation factors (factors II, VII, IX, and X), prolonging the prothrombin time and driving up the INR 2,5. Advanced portal hypertension induces severe splanchnic vasodilation and hyperdynamic circulation, which activates vasoconstrictor systems such as the renin-angiotensin-aldosterone system and the sympathetic nervous system 2,3. This neurohormonal cascade leads to renal vasoconstriction, reduced glomerular filtration, and avid sodium and water retention, culminating in functional renal failure (elevated serum creatinine) and refractory dilutional hyponatremia (depressed serum sodium) 1,2,7. The mathematical integration of these dynamic laboratory parameters captures the systemic collapse of liver, renal, and circulatory homeostasis 2,5.

MELD and MELD-Na score — Pathophysiological Cascade & Clinical Flowchart 1 Chronic Hepatic Insult Progressive hepatocellular loss and architectural distortion drive portal hypertension and declining synthetic function. 2 Haemodynamic & Renal Impairment Splanchnic vasodilation triggers neurohormonal activation, reducing effective arterial blood volume and glomerular filtration rate. 3 Multi-Organ Laboratory Derangement Elevations in bilirubin, creatinine, and INR reflect failing hepatic excretion, renal perfusion, and coagulation factor synthesis. 4 Prognostic Stratification Integration of biochemical markers into the MELD or MELD-Na formula yields a numerical estimate of 90-day waitlist mortality. 5 Therapeutic Prioritization & Transplant Allocation High numerical scores establish urgency for organ allocation, mitigating end-stage complications.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients typically present with progressive abdominal distension due to ascites, generalized fatigue, muscle wasting (sarcopenia), dark urine, pale stools, pruritus, and varying degrees of cognitive impairment secondary to hepatic encephalopathy3,7.
  • Physical Examination & Named Clinical Signs: Clinical evaluation reveals scleral icterus, jaundice, cutaneous stigmata of chronic liver disease (spider angiomata, palmar erythema, paper-money skin), caput medusae, shifting dullness on abdominal percussion, asterixis during neurological evaluation, and peripheral pitting edema3,7.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationCalculated MELD and MELD-Na mathematical algorithms utilizing standardized serum creatinine, total bilirubin, INR, and serum sodium values.
Laboratory PanelElevated total bilirubin, prolonged INR, elevated serum creatinine, and depressed serum sodium; complete blood count often demonstrates thrombocytopenia and leukopenia secondary to hypersplenism.
Imaging / Radiology (X-ray, US, CT, MRI)Abdominal ultrasonography with Doppler demonstrating a shrunken, nodular liver contour, patent or recanalized umbilical vein, splenomegaly, ascites, and reversal or sluggish portal vein flow; cross-sectional imaging evaluates for sarcopenia and hepatocellular carcinoma 3,6.
ECG / Histopathology / ProceduralElectrocardiogram to assess for cirrhotic cardiomyopathy (QT prolongation); liver biopsy or elastography confirms architectural fibrosis if etiology remains uncertain.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
MELD Formula ComponentsCalculated using natural logarithms: $9.57 \times \ln(\text{Cr}) + 3.78 \times \ln(\text{TBil}) + 11.2 \times \ln(\text{INR}) + 6.43$. Variables are bounded (minimum value of 1.0 applied if lower).
MELD-Na AdjustmentIncorporates serum sodium (Na): $\text{MELD-Na} = \text{MELD} + 1.32 \times (137 - Na) - [0.033 \times \text{MELD} \times (137 - Na)]$. Sodium is bounded between 125 and 137 mmol/L.
Score Ranges & 90-Day MortalityScore < 10: Low risk (~1.9% mortality); Score 10–19: Moderate risk (~6.0% mortality); Score 20–29: High risk (~19.6% mortality); Score 30–39: Very high risk (~52.6% mortality); Score ≥ 40: Critical risk (~71.3% mortality).
Transplant Allocation ThresholdA score exceeding 15 serves as the standard clinical threshold where the survival benefit of liver transplantation outweighs waitlist mortality risk.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Acute Liver Failure (Fulminant Hepatic Failure)Occurs in patients without pre-existing liver disease, characterized by rapid onset of coagulopathy and encephalopathy within 26 weeks; distinct from decompensated cirrhosis scored by MELD.
Acute-on-Chronic Liver Failure (ACLF)Marked by acute systemic inflammation, high-grade organ failures, and extremely elevated MELD scores, requiring intensive care unit admission rather than standard ward management 1,7.
Hepatorenal Syndrome (HRS-AKI)Functional renal failure occurring in advanced cirrhosis with marked portal hypertension, characterized by intense renal vasoconstriction and minimal response to volume expansion.
Obstructive Biliary Sepsis (e.g., Cholangitis)Presents with acute right upper quadrant pain, fever, and jaundice (Charcot triad); marked hyperbilirubinemia can elevate MELD scores independently of chronic hepatocellular failure.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Continuous monitoring in an inpatient or intensive care unit setting for patients with high MELD-Na scores; aggressive hemodynamic stabilization, correction of electrolyte disturbances, and management of acute variceal hemorrhage or encephalopathy1,7.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): Administration of empirical third-generation cephalosporins (e.g., ceftriaxone 2 g IV every 24 hours) for suspected spontaneous bacterial peritonitis or empyema; targeted diuresis using spironolactone (100–400 mg orally daily) combined with furosemide (40–160 mg orally daily) for ascites; non-selective beta-blockers for portal hypertension; and lactulose titrated to achieve 2 to 3 soft bowel movements daily for hepatic encephalopathy1,7.
  • Surgical / Interventional Indications: Evaluation for orthotopic liver transplantation for candidates with a MELD score $\ge 15$ or significant complications of portal hypertension; consideration of transjugular intrahepatic portosystemic shunt (TIPS) placement in selected patients with refractory ascites or recurrent variceal bleeding preserved against acute liver failure2,5.

Complications & Prognosis

  • Key Acute and Chronic Complications: Spontaneous bacterial peritonitis, spontaneous bacterial empyema, hepatorenal syndrome, refractory ascites, hepatic encephalopathy, coagulopathy-related hemorrhage, and hepatopulmonary syndrome1,3,7.
  • Mortality and Morbidity Data: Mortality correlates directly with incremental increases in the MELD and MELD-Na score; patients presenting with scores exceeding 30 face substantial short-term mortality risks approaching 50% to 70% within 90 days without emergency organ transplantation2,7.
  • Prognostic Factors: Presence of sarcopenia, acute-on-chronic liver failure grade, refractory hyponatremia, and failure of initial medical stabilization serve as robust negative prognostic indicators for waitlist and post-transplant survival1,3,7.